Martin E Hale Selected Research

Hydrocodone (Dihydrocodeinone)

1/2017	Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
5/2016	Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
11/2015	Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
9/2015	Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
1/2015	Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain.
1/2014	A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin E Hale Research Topics

Disease

13	Pain (Aches) 10/2016 - 01/2005
7	Low Back Pain (Lumbago) 05/2016 - 01/2005
4	Chronic Pain 01/2017 - 01/2014
3	Cancer Pain 01/2021 - 09/2012
3	Nausea 11/2015 - 02/2007
3	Constipation 11/2015 - 02/2007
2	Opioid-Induced Constipation 01/2021 - 01/2020
2	Neoplasms (Cancer) 12/2012 - 09/2012
1	Sensorineural Hearing Loss 05/2016
1	Opioid-Related Disorders (Opiate Addiction) 09/2015
1	Acute Pain 01/2015
1	Osteoarthritis 01/2015
1	Postoperative Pain 01/2015
1	Vomiting 01/2015
1	Sleepiness 02/2007
1	Back Pain (Backache) 09/2005
1	Spasm (Spasms) 09/2005

Drug/Important Bio-Agent (IBA)

13	Opioid Analgesics (Opioids)IBA 01/2020 - 01/2005
6	Hydrocodone (Dihydrocodeinone)FDA LinkGeneric 01/2017 - 01/2014
5	Pharmaceutical PreparationsIBA 11/2015 - 12/2012
4	Analgesics (Analgesic Drugs)IBA 11/2015 - 01/2005
3	TabletsIBA 01/2017 - 01/2015
3	Hydromorphone (Dilaudid)FDA LinkGeneric 01/2013 - 09/2012
2	naldemedineIBA 01/2021 - 01/2020
2	Abuse-Deterrent FormulationsIBA 10/2016 - 01/2015
2	Oxycodone (Oxycontin)FDA LinkGeneric 01/2015 - 01/2005
2	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2015 - 01/2014
2	Oxymorphone (Numorphan)FDA LinkGeneric 02/2007 - 01/2005
1	Narcotic Antagonists (Opioid Antagonists)IBA 01/2020
1	Prostaglandins AIBA 09/2015
1	Naltrexone (ReVia)FDA LinkGeneric 01/2015
1	oxycodone naltrexone combinationIBA 01/2015
1	Delayed-Action PreparationsIBA 01/2014
1	Neuromuscular Agents (Skeletal Muscle Relaxants)IBA 09/2005
1	Ibuprofen (Motrin)FDA LinkGeneric 09/2005
1	cyclobenzaprine FDA LinkGeneric 09/2005
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 09/2005

Therapy/Procedure

4	Therapeutics 01/2020 - 01/2005
2	Analgesia 05/2016 - 01/2015
1	Arthroplasty 01/2015
1	Operative Surgical Procedures 01/2015
1	Orthopedic Procedures 01/2015
1	Hip Replacement Arthroplasty (Total Hip Replacement) 01/2015